scholarly journals Ursolic acid inhibits breast cancer growth by inhibiting proliferation, inducing autophagy and apoptosis, and suppressing inflammatory responses via the PI3K/AKT and NF-κB signaling pathways in vitro

2017 ◽  
Vol 14 (4) ◽  
pp. 3623-3631 ◽  
Author(s):  
Juan Luo ◽  
Yan-Ling Hu ◽  
Hong Wang
Keyword(s):  
Breast Cancer ◽  
Signaling Pathways ◽  
Ursolic Acid ◽  
Inflammatory Responses ◽  
Cancer Growth ◽  
Breast Cancer Growth

scholarly journals Small molecule STAT3 inhibitor, 6Br-6a suppresses breast cancer growth in vitro and in vivo

2020 ◽  
Vol 121 ◽  
pp. 109502 ◽  
Author(s):  
Zhe Liu ◽  
Xianmin Ge ◽  
Yuchen Gu ◽  
Yingying Huang ◽  
Hao Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Small Molecule ◽  
Cancer Growth ◽  
Breast Cancer Growth

Specific endothelin-A-receptor antagonist ZD4054 inhibits breast cancer growth in vitro and in vivo

2008 ◽  
Vol 68 (S 01) ◽  
Author(s):  
M Smollich ◽  
M Götte ◽  
J Fischgräbe ◽  
I Radke ◽  
L Macedo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Receptor Antagonist ◽  
Cancer Growth ◽  
Endothelin A Receptor ◽  
Endothelin A ◽  
Breast Cancer Growth

Abstract A09: Development of epigenetic-based strategies for blocking breast cancer growth, invasion, and metastasis in vitro and in vivo

2018 ◽  
Author(s):  
Niaz Mahmood ◽  
David Cheishvili ◽  
Ani Arakelian ◽  
William J. Muller ◽  
Imrana Tanveer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Growth ◽  
Invasion And Metastasis ◽  
Breast Cancer Growth

Lithocarpus Polystachyus Rehd Leaf Aqueous Extract Inhibits Human Breast Cancer Growth In Vitro and In Vivo

2014 ◽  
Vol 66 (4) ◽  
pp. 613-624 ◽  
Author(s):  
Caiyu Lin ◽  
Li Wang ◽  
Hong Wang ◽  
Shengtao Fang ◽  
Quanbo Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Aqueous Extract ◽  
Human Breast Cancer ◽  
Cancer Growth ◽  
Human Breast ◽  
Leaf Aqueous Extract ◽  
Breast Cancer Growth

scholarly journals OP449 inhibits breast cancer growth without adverse metabolic effects

2017 ◽  
Vol 24 (10) ◽  
pp. 519-529 ◽  
Author(s):  
Gadi Shlomai ◽  
Zara Zelenko ◽  
Irini Markella Antoniou ◽  
Marilyn Stasinopoulos ◽  
Aviva Tobin-Hess ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Recurrence ◽  
Serum Triglyceride ◽  
Metabolic Effects ◽  
Cancer Growth ◽  
Cholesterol Levels ◽  
Body Weights ◽  
Insulin Receptor Signaling ◽  
Breast Cancer Growth

Hyperinsulinemia is associated with a decrease in breast cancer recurrence-free survival and overall survival. Inhibition of insulin receptor signaling is associated with glycemic dysregulation. SET is a direct modulator of PP2A, which negatively regulates the PI3K/AKT/mTOR pathway. OP449, a SET inhibitor, decreases AKT/mTOR activation. The effects of OP449 treatment on breast cancer growth in the setting of pre-diabetes, and its metabolic implications are currently unknown. We found that the volumes and weights of human MDA-MB-231 breast cancer xenografts were greater in hyperinsulinemic mice compared with controls (P < 0.05), and IR phosphorylation was 4.5-fold higher in these mice (P < 0.05). Human and murine breast cancer tumors treated with OP449 were 47% and 39% smaller than controls (P < 0.05, for both, respectively). AKT and S6RP phosphorylation were 82% and 34% lower in OP449-treated tumors compared with controls (P < 0.05, P = 0.06, respectively). AKT and S6RP phosphorylation in response to insulin was 30% and 12% lower in cells, pre-treated with OP449, compared with control cells (P < 0.01, P < 0.05, respectively). However, even with decreased AKT/mTOR activation, body weights and composition, blood glucose and plasma insulin, glucose tolerance, serum triglyceride and cholesterol levels were similar between OP449-treated mice and controls. Xenografts and liver tissue from OP449-treated mice showed a 64% and 70% reduction in STAT5 activation, compared with controls (P < 0.01 and P = 0.06, respectively). Our data support an anti-neoplastic effect of OP449 on human breast cancer cells in vitro and in xenografts in the setting of hyperinsulinemia. OP449 led to the inhibition of AKT/mTOR signaling, albeit, not leading to metabolic derangements.

AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo

2020 ◽  
Vol 172 ◽  
pp. 113771 ◽  
Author(s):  
Peng-Chao Zhang ◽  
Xiao Liu ◽  
Man-Mei Li ◽  
Yan-Yan Ma ◽  
Hong-Tao Sun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hsp90 Inhibitor ◽  
Cancer Growth ◽  
Breast Cancer Growth

scholarly journals Aponecrotic, antiangiogenic and antiproliferative effects of a novel dextran derivative on breast cancer growth in vitro and in vivo

2002 ◽  
Vol 135 (8) ◽  
pp. 1859-1871 ◽  
Author(s):  
Mélanie Di Benedetto ◽  
Anna Starzec ◽  
Bruno M Colombo ◽  
Dominique Briane ◽  
Gérard Y Perret ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Growth ◽  
Antiproliferative Effects ◽  
Breast Cancer Growth

Abstract P5-05-05: Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds

2020 ◽  
Author(s):  
Benita S. Katzenellenbogen ◽  
Yvonne Ziegler ◽  
Mary J Laws ◽  
Valeria S. Guillen ◽  
SungHoon Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Growth ◽  
New Class ◽  
Breast Cancer Growth
Sign in / Sign up

Export Citation Format

Share Document